antibody drug conjugate Archives

Can SIM0505’s Fast Track designation reshape the development outlook for NextCure, Inc. in ovarian cancer?

By Soujanya Ravi on April 7, 2026 Pharma & Biotech

Can SIM0505’s Fast Track win accelerate NextCure’s ovarian cancer strategy? Read the full PDN analysis on risks, ASCO data, and regulatory outlook.

What Zai Lab’s latest oncology data reveal about its long-term positioning in ADC and immunotherapy markets

By Pallavi Madhiraju on March 19, 2026 Pharma & Biotech

Zai Lab presents new oncology data at AACR 2026. Discover what its ADC and immunotherapy pipeline could mean for future cancer treatment strategies.

Biocytogen and IDEAYA Biosciences push IDE034 into the clinic as dual-antigen ADC strategies mature

By Pallavi Madhiraju on March 1, 2026 Pharma & Biotech

IDEAYA Biosciences doses first patient in IDE034 Phase 1 trial. Discover what this bispecific ADC means for solid tumor therapy.

Can BioAtla’s Oz-V set a new standard in ROR2-targeted therapy for head and neck cancer?

By Pallavi Madhiraju on January 1, 2026 Pharma & Biotech

BioAtla and GATC Health advance Ozuriftamab Vedotin into a Phase 3 trial for OPSCC via SPV financing. Discover how this targets cancer and aging together.